AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03740555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo multiple ascending doses
Description: Placebo, multiple ascending doses, Intravenous route, Multiple doses, daily for 7 days, matching placebo
Study NCT02848365 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation
Description: Endotracheal intubation will be done with any of these equipments
Study NCT03917472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab
Description: Intravitreal injection
Study NCT03917472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Intravitreal injection
Study NCT04596709 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitalose
Description: dissolved in water
Study NCT04596709 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: isomaltulose
Description: dissolved in water
Study NCT04596709 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: sucrose
Description: dissolved in water
Study NCT04596709 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: glucose
Description: dissolved in water
Study NCT02479698 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic BK-specific Cytotoxic T-lymphocytes
Description: Given IV
Study NCT02479698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01190267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asenapine
Description: asenapine 2.5 mg or 5.0 mg sublingual tablets, administered BID
Study NCT02589249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AyuFlex
Description: Active product
Study NCT02589249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03568682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional counseling + urban gardening
Description: Peer nutritional counseling and urban gardens
Study NCT03727126 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic esophagectomy
Description: Removal of the esophagus and its draining lymph nodes using robotic surgical instruments
Study NCT03727126 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracolaparoscopic esophagectomy
Description: Removal of the esophagus and its draining lymph nodes using conventional thoracoscopic and laparoscopic techniques
Study NCT03727152 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: generic single tablet TAF/FTC/DTG
Description: HIV-infected adults who are virologically suppressed and on protease inhibitor/ritonavir are switched to generic single tablet regimen of tenofovir alafenamide/emtricitibine/dolutegravir
Study NCT01839617 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Early parenteral nutrition
Study NCT00089895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous; delivery to match eptifibatide to maintain blind
Study NCT04078035 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Socio-evaluative speech task
Description: 5-minute speech task designed to induce physiological arousal in a laboratory setting.
Study NCT04078035 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control, Quiet Rest
Description: 5-minute quiet rest period.
Study NCT03835637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIC-101
Description: Capsule or oral suspension
Study NCT01839617 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Late parenteral nutrition
Study NCT02853669 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Lumber Plexus Block
Description: (30 cc of 0.25% of bupivacaine, via a 22-gauge 2-inch Stimuplex A needle) with nerve stimulator confirmation. The type of motor response (e.g., quadriceps, patellar) and the minimum current needed were recorded. Ultrasound pictures (preinjection and postinjection) were obtained to verify proper local anesthetic placement.
Study NCT02853669 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adductor canal block
Description: ultrasound-guided Adductor Canal Block (15 cc of 0.5% of bupivacaine)
Study NCT03250767 — intervention group
Intervention type: DEVICE
Intervention: Integra Titan Modular Shoulder System 2.5
Description: Primary Shoulder Joint Replacement
Study NCT03841968 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic needle tip positioning under ultrasound-guidance
Description: The tip of needle is positioned under ultrasound-guidance using dynamic short-axis view.
Study NCT03841968 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional long-axis view
Description: The tip of needle is positioned under ultrasound-guidance using conventional long-axis in-plane view.
Study NCT00200109 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Occipital Nerve Stimulation
Description: Each group had a different plan
Study NCT03902717 — intervention group
Intervention type: PROCEDURE
Intervention: Minimally invasive cardiac surgery
Description: Patients will undergo minimally invasive cardiac surgery
Study NCT00405522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol 2.0 mg/kg + Remifentanil 1.5 ug/kg
Description: Patients in this arm of the study will receive 2.0 mg/kg propofol + 1.5 ug/kg remifentanil. An anesthesiologist will inject propofol mixed with lidocaine, followed immediately by remifentanil, diluted with 0.9% saline to a volume of 3 ml and administered as a bolus.
Study NCT00405522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol 4.0 mg/kg + Remifentanil 0.5 ug/kg
Description: Patients in this arm of the study will receive 4.0 mg/kg propofol + 0.5 ug/kg remifentanil. An anesthesiologist will inject propofol mixed with lidocaine, followed immediately by remifentanil, diluted with 0.9% saline to a volume of 3 ml and administered as a bolus.
Study NCT03608657 — intervention group
Intervention type: DRUG
Intervention: Apremilast
Description: Apremilast
Study NCT03933670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Carbon C 13 Pyruvate
Description: Given IV
Study NCT03933670 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Undergo MRSI
Study NCT03933670 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI Ultrasound Fusion Guided Biopsy
Description: Undergo MR/US fusion-guided prostate biopsy
Study NCT03128320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1193397
Description: Single dose of 1 mg BAY1193397 given in the fasted state
Study NCT03128320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1193397
Description: Single dose of 5 mg BAY1193397 given in the fasted state
Study NCT03128320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo given in the fasted state
Study NCT00791661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1006
Description: MK-1006 capsules in single oral doses beginning at 15 mg and rising to 45 mg in Panel A, beginning at 60 mg and rising to 80 mg and 60 mg fed state in Panel B, or beginning at 100 mg and rising to 170 mg in Panel C.
Study NCT00791661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to MK-1006 in a single oral dose
Study NCT00658775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium
Description: Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.
Study NCT00658775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Esomeprazole 40 mg capsule, once daily for 4-8 weeks.
Study NCT01129349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oprozomib
Description: Oral administration of Oprozomib on Days 1-5 of a 14 day cycle
Study NCT04017832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Oral semaglutide to be taken every morning in a fasting state, to be followed by sitagliptin placebo after 30 minutes. Only then participants can have their first meal of the day and their pre-study metformin tablets
Study NCT04017832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin to be taken every morning, 30 minutes after taking the oral semaglutide placebo tablet. Then participants can have their first meal of the day and their pre-study metformin tablets
Study NCT04017832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (oral semaglutide)
Description: Placebo tablet to be taken first thing in the morning
Study NCT04017832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (sitagliptin)
Description: Placebo tablet to be taken 30 minutes after oral semaglutide
Study NCT03430401 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perceptual-based memory encoding
Description: It will run for 12 weeks with a 1-hour training session each week, supervised by a rehabilitation professional.~In addition, two 30-minute home-based training sessions will be completed by participants. In the home training session, participants will practice specific daily tasks that are covered in the previous professional-led session through the use of the computer-based intervention.
Study NCT03430401 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Semantic-based memory encoding
Description: It will run for 12 weeks with a 1-hour training session each week, supervised by a rehabilitation professional.~In addition, two 30-minute home-based training sessions will be completed by participants. In the home training session, participants will practice specific daily tasks that are covered in the previous professional-led session through the use of the computer-based intervention.
Study NCT03430401 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive stimulation
Description: The frequency, duration and the number of sessions will be consistent with the experimental interventions.
Study NCT03192618 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant transarterial chemoinfusion (TAI)
Description: transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
Study NCT03192618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
Description: oxaliplatin, calcium folinate, and 5-FU
Study NCT03219359 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant
Description: Hematopoietic stem cell transplantation
Study NCT03219359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days 1 and 2: Cyclophosphamide 2gm/m2/day x 2 days (total dose 4gm/m2) Day 3 until leukapheresis: G-CSF 10μg/kg/day to CD34+ >20x104/ml then leukapheresis daily to collection goal
Study NCT03219359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Day -6 to -3: Cyclophosphamide 50 mg/kg/day (200 mg/kg total dose)
Study NCT03219359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Day -3 to -1: 2.5 mg/kg/day (7.5 mg/kg total dose)
Study NCT03219359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Day -3 to -1: 1 gram prior to each ATG dose
Study NCT03219359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Starting first day after discharge from transplant admission, then 2 weeks after 1st infusion, 4 weeks after 2nd infusion, followed by every 8 weeks for 52 weeks (8 doses)
Study NCT05035667 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT04756154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHG/IPA Surgical skin preparation
Description: Apply topically to the inguinal region for 2 minutes
Study NCT04756154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHG/IPA Surgical skin preparation
Description: Apply topically to the inguinal region for 2 minutes
Study NCT04756154 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Apply topically to the inguinal region for 2 minutes
Study NCT02164097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODSH
Study NCT01234649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin XR plus placebo
Description: Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated
Study NCT01234649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR plus liraglutide
Description: Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)
Study NCT04192474 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Flexible cystoscopy
Description: Treatment with the investigational device: Ambu® aScope™ 4 Cysto
Study NCT04296890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab Soravtansine
Description: Mirvetuximab Soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα mAb M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.
Study NCT04663568 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Levonorgestrel-releasing intrauterine system
Description: Levonorgestrel-releasing intrauterine system will be inserted during the menstrual cycle
Study NCT01088529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: 1000 mg oral daily for 3 months followed by a prostatectomy.
Study NCT01088529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg orally daily.
Study NCT01088529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRHa
Description: LHRH analogue (either leuprolide or goserelin): Leuprolide is an intramuscular injection, and goserelin subcutaneous (under skin) of abdomen, given either 1 injection every 3 months or 1 injection each month for 3 months.
Study NCT04540484 — intervention group
Intervention type: OTHER
Intervention: Screening
Description: Blood test screening for covid
Study NCT04658186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB0599
Description: Drug: UCB0599 Pharmaceutical form: Granules in capsules Route of administration: Oral use Participants will receive UCB0599 in a pre-specified sequence during the Treatment Period.
Study NCT04658186 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo Pharmaceutical form: Capsules Route of administration: Oral use Participants will receive Placebo in a pre-specified sequence during the Treatment Period.
Study NCT02210819 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Cohort participants are classified as rivaroxaban patient, if the patient receives initial rivaroxaban VTE treatment. Dosing according to daily clinical routine
Study NCT02210819 — intervention group
Intervention type: DRUG
Intervention: Recommended VTE pharmacological treatments according to international guidelines
Description: Cohort participants are classified as Standard of care patients, if the patient receives recommended VTE pharmacological treatments according to international guidelines, e.g. unfractionated heparin, LMWH, fondaparinux, VKA, if these are also approved pharmacological treatments for VTE in the respective country. Dosing according to daily clinical routine.
Study NCT03065114 — intervention group
Intervention type: OTHER
Intervention: PGS
Description: chromosome abnormality test from PGS and relationship between embryo development
Study NCT01535274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspired oxygen fraction / end tidal carbon dioxide
Description: Following induction of anesthesia, FIO2 and minute ventilation will be sequentially adjusted to achieve:~1. FIO2 30% (70% nitrogen), PETCO2 30mmHg - supine position.~2. FIO2 30% (70% nitrogen), PETCO2 30mmHg - beach chair position.~3. FIO2 100%, PETCO2 30mmHg - beach chair position.~4. FIO2 100%, PETCO2 45mmHg - beach chair position.~5. FIO2 30% (70% nitrogen), PETCO2 30mmHg - beach chair position.
Study NCT02168543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Study NCT02168543 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02447835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine is approved for the treatment of schizophrenia and mania associated with bipolar disorder. Olanzapine is a psychotropic agent that belongs to the thienobenzodiazepine class. The chemical designation is 2-methyl-4-4methyl-1 piperazinyl-10H-thienol (2,3-b)\[1,5\]benzodiazepine. The molecular formula is C17H20N4S which corresponds to a molecular weight of 312.44.Olanzpine is a yellow crystalline solid which is practically insoluble in water. Olanzapine is a selective monoaminergic antagonist with high affinity binding to the following receptors:5HT2A2C, 5HT6, dopamine 2-4, histamine H1, and adrenergic α-1. In addition olanzapine is an antagonist with moderate affinity for muscarinic M1-5 and 5HT3. The mechanism of action of olanzapine is unknown although it may be mediated through a combination of dopamine and serotonergic type 2 receptors.
Study NCT02447835 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine is approved for the treatment of schizophrenia and mania associated with bipolar disorder. Olanzapine is a psychotropic agent that belongs to the thienobenzodiazepine class. The chemical designation is 2-methyl-4-4methyl-1 piperazinyl-10H-thienol (2,3-b)\[1,5\]benzodiazepine. The molecular formula is C17H20N4S which corresponds to a molecular weight of 312.44.Olanzpine is a yellow crystalline solid which is practically insoluble in water. Olanzapine is a selective monoaminergic antagonist with high affinity binding to the following receptors:5HT2A2C, 5HT6, dopamine 2-4, histamine H1, and adrenergic α-1. In addition olanzapine is an antagonist with moderate affinity for muscarinic M1-5 and 5HT3. The mechanism of action of olanzapine is unknown although it may be mediated through a combination of dopamine and serotonergic type 2 receptors.
Study NCT02081456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soft Tissue Mobilization
Description: Patients in the STM group received treatment in supine, with their head resting on one pillow and the involved UE positioned in abduction and external rotation to preload the neural structures of the upper limb. Manual pressure was applied to the soft tissues of the upper quadrant in a deep, stroking manner with the intention to improve the mobility of the soft tissues surrounding the pathway of the neural structures of the upper limb as well as any tender or tight tissues. The therapist spent approximately 7 minutes on the neck and scapular region, 4 minutes on the upper arm, and 4 minutes on the forearm and hand. The therapist was allowed to vary the time spent on each region according to his/her assessment of the patient's condition. The procedure lasted a total of 15 minutes.
Study NCT04624958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib and Rituximab
Description: Zanubrutinb 160mg PO BID d1-28; Rituximab 375mg/m2 iv.drip d1.
Study NCT04624958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-DHAOx
Description: Rituximab 375mg/m2 iv.drip d1; Dexamethasone 20mg iv.drip d1-4; Cytarabine 2000mg/m2 (1000mg/m2 for patients aged over 65) iv.drip d2,3 Oxaliplatin 130mg/m2 iv.drip d1.
Study NCT04624958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib Maintenance
Description: Zanubrutinb 160mg PO BID.
Study NCT02081456 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Ultrasound
Description: Patients received therapeutic US applied for a period of 5 minutes to the most painful region of the neck, then a second 5-minute dose at the most painful region of the upper extremity. The US dose was 0.5 w/cm2, with sonation time 50% and frequency 1 MHz.40,52 The patient lay supine with the hand of the involved upper extremity placed on the abdomen and the elbow supported on a pillow. The two US doses and interaction time with the patient lasted a total of 15 minutes in an attempt to have equal patient/therapist contact between the two groups.
Study NCT02538770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid diagnostics using Anyplex TMII RV16 Detection
Description: Rapid diagnostics using Anyplex TMII RV16 Detection, i.e. physician receives results of respiratory virus PCR as soon as they are available
Study NCT02538770 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed diagnostics Anyplex TMII RV16 Detection
Description: Delayed diagnostics Anyplex TMII RV16 Detection, i.e. physician receives results of respiratory virus PCR after one week delay unless specifically solicited
Study NCT01424436 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK933776
Description: 1mg/kg dose group
Study NCT01424436 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK933776
Description: 3mg/kg dose group
Study NCT01424436 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK933776
Description: 6mg/kg dose group